Cinchona urea compounds having 3,5-diiodophenyl moieties were subjected to Yamamoto coupling polymerization to afford the chiral urea polymers. These polymers showed high activities as heterogeneous catalysts in asymmetric Michael reactions comparable with those of the corresponding monomeric catalyst in solution systems. Furthermore, the polymeric catalysts are easily recovered from their reaction mixtures due to their insolubility and can be reused several times without loss of catalytic activity.

Herein, we developed an NMR protocol to access the chiral recognition of lipoic acid, which demonstrates a remote stereocenter, in a simple and rapid procedure employing cinchonidine in CDCl3.

Hexahydrocurcumin (HHC) and octahydrocurcumin (OHC) were synthesized, and their enantiomers were separated using supercritical fluid chromatography. The absolute configurations (ACs) of HHC and OHC were independently determined using experimental measurements and quantum theoretical predictions of vibrational circular dichroism, electronic circular dichroism, and optical rotatory dispersion. These studies lead to AC assignments of (-)-(R)-HHC and (+)-(R,R)-OHC. The AC of OHC is further confirmed by its structure determined from single crystal x-ray diffraction.

ChiralityVolume 34, Issue 12 p. 1491-1493 EDITORIAL Special issue: Chirality in pharmaceutical research and development Simona Collina, Simona Collina University of Pavia, Pavia, ItalySearch for more papers by this authorSimone Lucarini, Simone Lucarini Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, ItalySearch for more papers by this authorJordi Benet-Buchholz, Jordi Benet-Buchholz Institute of Chemical Research of Catalonia (ICIQ), The Barcelona Institute of Science and Technology, Tarragona, SpainSearch for more papers by this authorOliver Trapp, Oliver Trapp University of Munich, Munich, GermanySearch for more papers by this authorGennaro Pescitelli, Gennaro Pescitelli University of Pisa, Pisa, ItalySearch for more papers by this authorNina Berova, Nina Berova Columbia University, New York, New York, USASearch for more papers by this author Simona Collina, Simona Collina University of Pavia, Pavia, ItalySearch for more papers by this authorSimone Lucarini, Simone Lucarini Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, ItalySearch for more papers by this authorJordi Benet-Buchholz, Jordi Benet-Buchholz Institute of Chemical Research of Catalonia (ICIQ), The Barcelona Institute of Science and Technology, Tarragona, SpainSearch for more papers by this authorOliver Trapp, Oliver Trapp University of Munich, Munich, GermanySearch for more papers by this authorGennaro Pescitelli, Gennaro Pescitelli University of Pisa, Pisa, ItalySearch for more papers by this authorNina Berova, Nina Berova Columbia University, New York, New York, USASearch for more papers by this author First published: 27 October 2022 https://doi.org/10.1002/chir.23510 [This article is part of the Special issue: Chirality in Pharmaceutical Research and Development. See the first articles for this special issue previously published in Volumes 34:3, 34:6, 34:7, 34:8, 34:9, 34:10, and 34:11. More special articles will be found in this issue as well as in those to come.] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume34, Issue12December 2022Pages 1491-1493 This article also appears in:Chirality in Pharmaceutical Research and Development RelatedInformation

Chiral carbon nanoparticles (CNPs) represent a rapidly evolving area of research for optical and biomedical technologies. Similar to small molecules, applications of CNPs as well as fundamental relationships between their optical activity and structural asymmetry would greatly benefit from their enantioselective separations by chromatography. However, this technique remains in its infancy for chiral carbon and other nanoparticles. The possibility of effective separations using high performance liquid chromatography (HPLC) with chiral stationary phases remains an open question whose answer can also shed light on the components of multiscale chirality of the nanoparticles. Herein, we report a detailed methodology of HPLC for successful separation of chiral CNPs and establish a path for its future optimization. A mobile phase of water/acetonitrile was able to achieve chiral separation of CNPs derived from L‐ and D‐cysteine denoted as L‐CNPs and D‐CNPs. Molecular dynamics simulations show that the teicoplanin‐based stationary phase has a higher affinity for L‐CNPs than for D‐CNPs, in agreement with experiments. The experimental and computational findings jointly indicate that chiral centers of chiral CNPs are present at their surface, which is essential for the multiple applications of these chiral nanostructures and equally essential for interactions with biomolecules and circularly polarized photons.

No abstract is available for this article.

The cover image is based on the Review Article Recent advances in the field of chiral crystallization by Joshua I. Putman and Daniel W. Armstrong https://doi.org/10.1002/chir.23492.

No abstract is available for this article.

No abstract is available for this article.

Chiral high-performance liquid chromatography (HPLC) analysis of natural pericosine A, which appeared in literature first in 1977, from Periconia byssoides was conducted using a column CHIRALPAK® AD-H to determine the enantiomeric composition of the original mixture which was found to be 68: 32 mixtures of (+)- and (-)-enantiomer, respectively. Furthermore, two independently isolated samples of pericosine A from the same fungus were also analyzed to show the two peaks in the HPLC charts at approximate 1:1 ratio. These results concluded that pericosine A derived from Periconia byssoides was indeed an enantiomeric mixture. Synthesized enantiomers were subjected to evaluation of antitumor activity against three kinds of tumor cells (p388, L1210, HL-60), indicating moderate cytotoxicity against all three kinds of tumor cell lines, but significant difference in potency between the enantiomers was not observed. In contrast, when both the enantiomers of pericosine A were evaluated against five kinds of glycosidases-inhibitory activities (α- and β-glucosidases, α- and β-galactosidases, and α-mannosidase), an apparent difference on anti-glycosidase assay was found between the enantiomers: (-)-pericosine A inhibited α-glucosidase at IC50 : 2.25 mM, and β-galactosidase at IC50 : 5.38 mM, albeit the (+)-enantiomer showed inactivity against these five enzymes.